Castle Biosciences, Inc. (CSTL) Financial Statements
Castle Biosciences, Inc. (CSTL) reported trailing twelve-month revenue of $357.3M (up 3.2% year on year) and net income of -$19.4M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$489000.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CSTLCastle Biosciences, Inc.Follow CSTL — free
—
Price chart with a free account
- Market cap
- 1.0B
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.9 | 62.6 | 94.1 | 137.0 | 219.8 | 332.1 | 344.2 | 357.3 | |
| Gross profit | 44.6 | 53.0 | 78.3 | 105.0 | 174.8 | 271.9 | 273.2 | 276.0 | |
| Research & development | 7.4 | 13.3 | 29.6 | 44.9 | 53.6 | 52.0 | 51.9 | 55.4 | |
| Operating income | 7.3 | -6.5 | -40.1 | -72.9 | -68.0 | 8.7 | -42.8 | -32.1 | |
| Pre-tax income | 5.3 | -10.2 | -40.0 | -68.9 | -57.4 | 21.6 | -29.5 | -19.2 | |
| Income tax | 0.1 | 0.1 | -8.7 | -1.8 | 0.1 | 3.3 | -5.4 | 0.2 | |
| Net income | 5.3 | -10.3 | -31.3 | -67.1 | -57.5 | 18.2 | -24.2 | -19.4 | |
| Diluted EPS ($) | -0.21 | -0.54 | -1.24 | -2.58 | -2.14 | 0.62 | -0.83 | -0.65 | |
| Diluted shares (mn) | 8.7 | 18.9 | 25.1 | 26.1 | 26.8 | 29.3 | 29.0 | — |
USD millions · SEC XBRL
Castle Biosciences, Inc. — questions
- What is Castle Biosciences, Inc.'s revenue?
- $357.3M over the twelve months to 2026-06-30, up 3.2% year on year, from its 10-Q and 10-K filings.
- What is Castle Biosciences, Inc.'s net income?
- -$19.4M over the twelve months to 2026-06-30.
- What is Castle Biosciences, Inc.'s free cash flow?
- -$489000 over the twelve months to 2026-06-30.
- What are Castle Biosciences, Inc.'s diluted earnings per share?
- $-0.65 over the twelve months to 2026-06-30.
Every figure on this page comes from Castle Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.